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Abstract 
An accumulating body of literature has emerged in the past 25 years to show that Parkinson’s disease (PD) is 
not only a disorder of the brain but also of the gastrointestinal tract and more generally of the gut-brain axis. 
Gastrointestinal symptoms occur in almost every PD patient at some point and in nearly every case examined 
pathologically autopsy studies find alpha-synuclein deposits, the pathological hallmarks of PD, in the enteric 
nervous system. This concept of ‘enteric synucleinopathy’ led to the hypothesis that the enteric nervous sys-
tem might play a pivotal role in the initiation and spreading of PD. Although this hypothesis opens up interest-
ing perspectives on the pathogenesis of neurodegenerative disorders, some important questions are still pend-
ing. The present opinion paper describes and compares the physiological and pathophysiological properties of 
alpha-synuclein in the brain and the enteric nervous system. We conclude that the existing data supports the 
existence of pathological alpha-synuclein species in the gut in PD. We also discuss if gut-brain interactions are 
important in other neurodegenerative disorders. 
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Abbreviations 
AD - Alzheimer’s disease, ENS - enteric nerv-
ous system, GI - Gastrointestinal, LB - Lewy bodies, 
LN - Lewy neurites, PD - Parkinson’s disease, PMCA 
- protein misfolding cyclic amplification, PSP - pro-
gressive supranuclear palsy 
The enteric nervous system (ENS) is an intricate 
neural network embedded within the gastrointes-
tinal (GI) tract and distributed from the lower oe-
sophagus to the rectum. Compared to other com-
ponents of the peripheral nervous system, the ENS 
shows some unique features that closely resemble 
the CNS and therefore it is sometimes referred to 
Opinion Piece 
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as ‘the brain-in-the-gut’ or the ‘second brain’ *1+ 
(Figure 1). This close homology between the CNS 
and ENS suggests that a disease process affecting 
the CNS could also involve its enteric counterpart. 
Parkinson’s disease (PD) is the best example of this 
assumption. PD is the most common synucleinopa-
thy (or synuclein proteinopathy), a group of neuro-
degenerative disorders characterized by a common 
pathological lesion composed of aggregates of al-
pha-synuclein in selectively vulnerable neuron 
populations in the CNS [2]. Although PD has tradi-
tionally been considered a disease of dopaminergic 
neurons in the substantia nigra, analyses of GI 
samples from PD patients have consistently found 
neural pathology, with the presence of alpha-
synuclein deposits being detected in the ENS in 
nearly every PD patient examined [3–11]. This has 
led to the emerging concept of enteric synucle-
inopathy. Although these observations open up 
interesting perspectives on the pathogenesis of 
neurodegenerative disorders, some important 
questions are still pending, among which are: what 
are the biochemical and pathological characteris-
tics of alpha-synuclein deposits in the ENS? Are 
they similar to those observed in the CNS? Is there 
any neuronal loss in the ENS in PD? Besides PD, are 
gut-brain interactions important in other neuro-
degenerative disorders? Here, we first provide a 
brief overview of the normal expression profiles of 
alpha-synuclein in the ENS, before discussing these 
questions and the arguments for and against the 
existence of enteric synucleinopathies. 
Alpha-synuclein is physiologically ex-
pressed by enteric neurons 
Alpha-synuclein was first isolated in 1988 from 
the electric organ of the Pacific electric ray Torpedo 
californica. In addition to its strong presynaptic 
localisation, Maroteaux et al., also identified alpha-
synuclein in the nucleus, thus accounting for the 
name ‘synuclein’ (SYNapse + NUCLEus) [12]. Several 
studies have documented the physiological func-
tion of alpha-synuclein in modulating synaptic vesi-
cle release [13]. Human alpha-synuclein, 140 amino 
acids in length, is mainly expressed by CNS neurons 
and erythrocytes and is composed of 3 different 
functional regions (Figure 2a) [13]. There is still 
open debate about the physiological structure of 
brain alpha–synuclein as some research groups 
concluded that it occurs as a helically folded te-
tramer [14], while others counterclaim that it exists 
primarily as a disordered monomer [15]. Alpha-
synuclein has a natural propensity to aggregate as 
amyloid structures in a nucleation-dependent pro-
cess in which monomers assemble via oligomers 
into fibrils [16] (Figure 2b). 
Alpha-synuclein is also expressed by enteric 
neurons. In rodents, guinea-pigs and human alpha-
synuclein positive neurons are present in the two 
plexuses of the ENS and along the entire digestive 
tract [5, 17, 18] (Figure 3). Using amine-reactive 
cross-linking, we showed that, unlike brain neu-
rons, alpha-synuclein exists primarily as a monomer 
in enteric neurons [19]. As far as we know, the ex-
pression of alpha-synuclein by enteric glial cells, the 
enteric counterpart of CNS astrocytes, has not been 
evaluated. Detailed immunohistochemical charac-
terisation showed that alpha-synuclein immunore-
active neurons are mostly cholinergic [17, 18] (Fig-
ure 1) and that alpha-synuclein is closely associated 
with the vesicular apparatus [20]. Although the role 
of alpha-synuclein in the ENS is still mostly un-
known, a recent study suggested that it is involved 
in the development and electrophysiological prop-
erties of enteric cholinergic neurons [21]. 
Does the ENS contain pathological 
aggregated forms of alpha-synuclein? 
Lewy bodies (LB) and Lewy neurites (LN) are 
the defining neuropathological characteristics of 
PD. LB typically appear in neuronal somata as eo-
sinophilic, rounded inclusions while LN are strand-
like structures observed in axons. In 1997, it was 
demonstrated that LB and LN isolated from PD 
brain were highly immunoreactive for alpha-
synuclein, thereby suggesting that this protein was 
one of the main components of Lewy pathology 
[22]. Subsequent work showed that alpha-synuclein 
in LB and LN was hyperphosphorylated at serine 
residue 129 [23] (Figure 2). Because alpha and 
phospho-alpha-synuclein immunohistochemical 
staining has a much greater sensitivity than hema-
toxylin and eosin staining for the detection of LB 
[24], this method quickly became the method of 
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Figure 1. Anatomical organisation and local reflexes of the enteric nervous system. The ENS is a neuronal network embedded within 
the GI tract and distributed from the lower oesophagus to the rectum. It is organized in two major ganglionated plexuses, the myenteric 
(MP or Auerbach’s plexus) mainly involved in the control of smooth muscle activity, and the submucosal (SMP or Meissner’s plexus), 
which regulates secretion (SN, secretory neurons) and microvasculature. Compared to other sections of the peripheral nervous system, 
the ENS shows unique features that closely resemble some of the CNS: it contains a variety of functionally distinct enteric neurons along 
with a vast repertoire of neurotransmitters and intercellular messengers which are the basis for enteric neurotransmission. It also har-
bours a prominent component of glial cells (EGC for enteric glial cells) which, like astrocytes in the CNS, contribute to support, protec-
tion and maintenance of the neural networks. Local distention of the intestinal wall and chemical contents in the gut lumen activate 
intrinsic primary afferent neurons (IPAN) located in both the SMP and MP. The IPAN projects both in oral and anal directions to synapse 
with interneurons (IN) and motor neurons (MN). Cholinergic (ACh) MN in red are excitatory while nitrergic (NO) MN in green are inhibi-
tory. The peristaltic reflex includes an ascending excitatory reflex mediated by cholinergic MN and elicits contraction of the circular or 
longitudinal smooth muscles located orally to the site of stimulation. The descending inhibitory reflex involves inhibitory nitrergic MN 
that elicit relaxation of the circular muscles and longitudinal muscles located anally to the site of stimulation. 
 
 
choice for the neuropathological diagnosis of PD 
[25]. Using this approach, several neuropathology 
laboratories demonstrated that LB and LN-like 
structures were observed in the ENS (in both the 
myenteric and submucosal plexus) in the vast ma-
jority of PD patients [3–7] (Figure 3). In some of 
these studies, proteinase K [3] or alkaline protease 
[7] pre-treatments were used primarily to unmask 
antigens and enhance immunolabeling, but such 
treatments might also allow protease-resistant 
misfolded, aggregated and hyperphosphorylated 
alpha-synuclein to be distinguished from soluble 
forms of the protein. On the whole these findings 
suggest that pathological aggregated alpha-
synuclein is present within the GI tract of PD sub-
jects. Two key issues should however be borne in 
mind. First, the mere detection of alpha-synuclein 
phosphorylated at serine 129 is not synonymous 
with aggregation since soluble alpha-synuclein is 
also physiologically phosphorylated at this residue 
[26]. Secondly, immunohistochemical approaches 
are not sufficient to show that alpha-synuclein is 
misfolded/aggregated; biochemical confirmation of 
altered solubility is required. Indeed, in the CNS, a 
comprehensive biochemical characterisation of 
alpha-synuclein forms in LB has already been car-
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ried out. Using one and two-dimensional immunob-
lot analysis with modification-specific synuclein 
antibodies and mass spectroscopy, Anderson et al. 
confirmed that the predominant modification of 
alpha-synuclein in LB was phosphorylation at serine 
129. They also found a set of additional characteris-
tic modifications including ubiquitination at amino-
terminal lysine residues and specific carboxy-
terminal truncations [27] (Figure 2). An additional 
property of alpha-synuclein aggregates found in 
diseased brains is their seeding ability: the amyloid 
fibrils formed by alpha-synuclein aggregates can act 
as templates for the conversion of physiological 
alpha-synuclein, resulting in the growth of the fi-
brils and spread of alpha-synuclein pathology [28]. 
How about the biochemical characterisation of 
alpha-synuclein in diseased ENS? There are some 
existing data but it is definitely less complete and 
robust than those available for the CNS. Using one 
and two-dimensional analysis of colonic biopsies, 
we were unable to detect any differences in the 
expression levels, phosphorylation or aggregation 
status of alpha-synuclein between controls and PD 
specimens [29]. These negative findings might 
however be explained by the relative sparsity of 
neuronal structures and/or alpha-synuclein inclu-
sions in the GI samples that were used; due to a 
shortage of samples, only 2 routine colonic biopsies 
per subject were pooled and analysed. However, 
when we had the opportunity to analyse 4 pooled 
biopsies per subject, we were able to detect acidic 
and high molecular weight alpha-synuclein species 
in the GI tract of PD patients but not controls, 
which likely represent hyperphosphorylated and 
aggregated forms of the protein, respectively 
(Lebouvier-Derkinderen unpublished results, Figure 
4). Such a pattern is reminiscent of that observed in 
PD brain [27] (Figure 4). The limitations of the two-
dimensional immunoblotting technique prompted 
us to use more sensitive approaches, based on the 
seeding efficiency of alpha-synuclein. Using an as-
say inspired by the protein misfolding cyclic ampli-
fication (PMCA) assay, we showed that GI biopsies 
from PD patients (2 to 4 biopsies per subject taken 
from the upper or lower GI tract) seeded alpha-
synuclein aggregation in 10 out of 18 cases [30]. 
More recently, Viviane Labrie and Patrik Brundin’s 
group focused on the vermiform appendix, a struc-
ture which is particularly enriched in alpha-
synuclein [31]. 
 
 
 
Figure 2. Alpha-synuclein structure and molecular mechanism of its oligomerisation and fibrillogenesis. (a) Schematic representation 
of alpha-synuclein, which is composed of 3 distinct regions : (i) an N-terminal domain (amino acids 1–60) that binds lipids and contains 
the lysines that are ubiquitinated (ii) a central domain known as the non-amyloid component (NAC) (amino acids 61–95) which is in-
volved in aggregation, and (iii) a C-terminal acidic tail (amino acids 96–140) accountable for most interactions with other proteins and 
small molecules and that contains most of the phosphorylation sites including serine 129. Some of the truncated C terminal forms of 
alpha-synuclein are also shown. (b) Illustration of the molecular steps involved in alpha-synuclein oligomerisation and fibrillogenesis 
leading to Lewy body formation. Soluble alpha-synuclein is natively unstructured and monomeric. Under pathological conditions, solu-
ble α-synuclein forms β-sheet-like oligomers (protofibrils), which convert into amyloid fibrils and eventually deposit in Lewy bodies. 
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Figure 3. Physiological expression of alpha-synuclein and phospho-alpha-synuclein histopathology in the ENS. Left: anti-alpha-
synuclein antibody Syn-1 was used to detect alpha-synuclein in the myenteric ganglia (colon) in a control subject devoid of neurodegen-
erative disorders; III tubulin antibody was used to label the neuronal network. Scale bar is 50 µm. Right: the colon from a PD patient 
was microdissected into mucosa, whole mount of submucosa and myenteric plexus. Each part was stained with an antibody specific for 
the phosphorylated form of alpha-synuclein. Phospho-alpha-synuclein histopathology with a LN-like pattern is observed in the mucosa 
(arrow, the asterisk is for the crypt) and submucosa, while a LB-like structure is found in the myenteric plexus. Scale bar is 40 µm. 
 
Using mass spectrometry, they identified full-
length alpha-synuclein together with a set of 10 
truncated forms in the healthy human appendix 
[32]. Additional experiments performed with an in 
vitro shaking assay (also inspired by the PMCA ap-
proach), showed that appendix lysates from either 
control or PD subjects seeded aggregation and 
truncation of alpha-synuclein. These intriguing and 
provocative findings suggest that aggregated and 
truncated alpha-synuclein are consistently found in 
the human healthy appendix, thereby supporting 
the assumption that the appendix may act as a 
reservoir for pathogenic forms of alpha-synuclein 
[31, 32]. 
 It has also been shown that pathological 
alpha-synuclein obtained from PD brain has the 
ability to trigger alpha-synuclein pathology in the 
CNS of rodents and non-human primates [33, 34]. 
For example, the intranigral inoculation of alpha-
synuclein-containing LB extracts obtained from PD 
brains leads to widespread alpha-synuclein pathol-
ogy together with dopaminergic neurodegenera-
tion in mice and monkeys [35]. For the sake of 
comparisons between brain and enteric alpha-
synuclein, it is important to know if pathological 
alpha-synuclein obtained from the GI tract shares 
the same pathogenic capacity. Although the precise 
answer to this question remains unknown, a recent 
study evaluated the effects of alpha-synuclein ag-
gregates from post-mortem PD stellate ganglia 
(pooled from 3 patients) injected into mouse brain 
[36]. Stellate ganglion is a paravertebral ganglion, 
which like the gut, exhibits marked Lewy pathology 
in almost all PD subjects [4, 37]. In contrast to the 
findings obtained with substantia nigra-derived 
alpha-synuclein, no pathological effects were ob-
served when peripheral aggregates from stellate 
ganglion were injected into the brain of wild-type 
mice, at least up to 6 months following injection 
[36]. This intriguing observation, which casts doubt 
on the pathogenicity of peripheral alpha-synuclein, 
requires replication using extracts from other pe-
ripheral organs affected by Lewy pathology, such as 
the GI tract or the salivary glands [3, 38]. 
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Figure 4. High molecular weight and post-translationally modified alpha-synuclein species in the GI tract of PD patients. Immunoblots 
of total mesencephalon lysates (A and B) from a control (A) and a PD patient autopsy sample (B), and immunoblots of colonic biopsy 
lysates (C and D) from a control (C) and PD patient (D) were resolved by two-dimensional PAGE using pH 3–10 IEF gradients. Immunob-
lots were probed with the alpha-synuclein antibody Syn-1. White asterisks mark full-length synuclein. Boxes highlight differences be-
tween PD patients and controls: acidic modifications of full-length monomer (solid boxes), and high molecular weight species (dotted 
boxes) are present in PD patients and absent in controls, in both substantia nigra and colonic biopsies (n=2); pI values and positions of 
molecular weight standards are indicated. An equivalent amount of protein was loaded in A-B and C-D, respectively. 
 
Is there any enteric neuronal loss in 
PD? 
In the substantia nigra of PD subjects, the 
presence of alpha-synuclein aggregates is accom-
panied by severe neuronal loss and clinicopatholog-
ical findings strongly suggest that the classical PD 
motor symptoms, including bradykinesia and hy-
pertonia, are driven primarily by neuronal loss ra-
ther than only the aggregation of alpha-synuclein 
[39]. As such, the quantitative evaluation of enteric 
neuron populations is important to determine the 
pathological underpinnings of GI symptoms, which 
are so frequently observed in PD [40]. With that 
said, and despite the publication of proposed 
guidelines and consensus techniques, the quantifi-
cation of submucosal and myenteric neuron num-
ber remains challenging [41], mainly because of the 
fishnet-like architecture of the ENS plexus. In the 
most comprehensive post-mortem study to date, 
Annerino et al. used formalin-fixed paraffin em-
bedded sections to compare myenteric neuron 
density along the length of the GI tract in 6 patients 
with PD and 12 controls. There were no differences 
in total myenteric neuron density between controls 
or patients in any segment examined [42]. Similar-
ly, when whole mounts of submucosa obtained 
from colonic biopsies were analysed by immuno-
histochemistry, no major decrease in neuronal 
density was observed in PD relative to controls in 
two independent studies that included a total of 58 
PD and 30 control cases [8, 43]. On the whole, the-
se data strongly suggest that enteric neuron loss is 
not a feature of PD. 
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Besides alpha-synuclein, are other 
aggregated proteins found in the 
ENS? 
The observation that alpha-synuclein deposits 
are a feature of PD gut logically leads to speculation 
that such a phenomenon might also occur in other 
neurodegenerative disorders such as tauopathies. 
Like alpha-synuclein, tau is physiologically ex-
pressed by enteric neurons. However, in contrast 
to the CNS neurons that express all six tau 
isoforms, adult human ENS primarily express only 
two tau isoforms [44]. Tau aggregates found in 
tauopathies generally contain tau in an elevated 
state of phosphorylation that is often aberrantly 
cleaved [45]. In a preliminary report, we analysed 
by Western blot colonic biopsies from 5 patients 
with probable progressive supranuclear palsy (PSP) 
using 2 different phospho-tau antibodies and one 
antibody specific for caspase-cleaved tau [44]. The 
phosphorylation and truncation patterns of tau in 
PSP were indistinguishable from those in controls 
[44]. In a subsequent study, Brittany Dugger et al. 
performed a comprehensive immunohistochemical 
analysis of the ENS in tauopathies. Using formalin 
fixed paraffin embedded sections, they examined 
the sigmoid colon in 26 PSP, 21 AD and 19 controls 
using one antibody for total tau and two phospho-
tau antibodies [46]. No differences in the staining 
pattern were observed between colonic specimen 
from tauopathy patients and controls [46].  
So, enteric synucleinopathy: myth or 
reality? 
Even if they are still preliminary, recent find-
ings and in particular the ones obtained with ultra-
sensitive amplification techniques such as PMCA, 
convincingly showed that alpha-synuclein aggre-
gates with seeding capacity are found in the ENS 
[30, 32]. It therefore seems justified to use the 
word ‘enteric synucleinopathy’. That said, some 
outstanding questions remain: (i) existing findings 
suggest that enteric neuron loss is not a feature of 
PD but there could be more subtle morphologic 
changes [47] that could be evaluated in the future 
using computer-assisted analysis of the enteric 
neurons [48] (ii) a comprehensive inventory of al-
pha-synuclein forms present the ENS from patients 
with PD still need to be carried out, as has already 
been performed for the CNS [27] (iii) the results 
obtained with PMCA need to be independently 
replicated and confirmed by others amplification 
techniques such as RT-QuIC (real-time quaking-
induced conversion) [49]. In addition, it still re-
mains to be determined if pathological alpha-
synuclein purified from the ENS is capable of pro-
moting alpha-synuclein pathology when intracere-
brally inoculated, as already demonstrated for CNS-
derived alpha-synuclein aggregates [50]. This is a 
critical issue with regard to PD pathogenesis as it 
has been speculated that enteric alpha-synuclein 
aggregates may spread to the CNS via the vagal 
connections. However, performing such experi-
ments, which require purification of LB-containing 
fractions from the gut, can be challenging due to 
the low frequency and density of aggregated alpha-
synuclein in the ENS [3, 51]. On the whole, current 
knowledge strongly supports the existence of en-
teric synucleinopathy and these data encourage 
future studies aimed at expanding our knowledge 
of peripheral pathology in neurodegenerative dis-
orders to gain clues that enable further under-
standing of the differential pathogenesis of these 
disorders.
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